Literature DB >> 17010341

Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564.

Hiroshi Harada1, Shinae Kizaka-Kondoh, Masahiro Hiraoka.   

Abstract

Under normoxic conditions the alpha-subunit of hypoxia-inducible factor (HIF-1alpha) protein is targeted for degradation by the von Hippel-Lindau (VHL) tumor suppressor protein acting as an E3 ubiquitin ligase. Recently, we developed a hypoxia-targeting protein, TOP3, which consisted of procaspase-3 with the VHL-mediated protein destruction motif of HIF-1alpha. This design enables procaspase-3 to be regulated similarly with HIF-1alpha, being degraded under normoxia while stabilized under hypoxia. Furthermore, stabilized TOP3 was cleaved by the hypoxic stress-induced endogenous caspases and thus the procaspase-3 was converted to active caspase-3 specifically under hypoxic conditions. These data demonstrated that the VHL-mediated protein destruction motif of HIF-1alpha endowed procaspase-3 with hypoxia-specific cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010341     DOI: 10.1016/j.febslet.2006.09.025

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Tumor hypoxia imaging.

Authors:  Xilin Sun; Gang Niu; Nicholas Chan; Baozhong Shen; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

2.  Hypoxia-induced human endonuclease G expression suppresses tumor growth in a xenograft model.

Authors:  P T Winnard; M Botlagunta; J B Kluth; S Mukadam; B Krishnamachary; F Vesuna; V Raman
Journal:  Cancer Gene Ther       Date:  2008-06-13       Impact factor: 5.987

3.  Involvement of decreased hypoxia-inducible factor 1 activity and resultant G1-S cell cycle transition in radioresistance of perinecrotic tumor cells.

Authors:  Y Zhu; T Zhao; S Itasaka; L Zeng; C J Yeom; K Hirota; K Suzuki; A Morinibu; K Shinomiya; G Ou; M Yoshimura; M Hiraoka; H Harada
Journal:  Oncogene       Date:  2012-06-18       Impact factor: 9.867

4.  In vivo imaging of HIF-active tumors by an oxygen-dependent degradation protein probe with an interchangeable labeling system.

Authors:  Takahiro Kuchimaru; Tetsuya Kadonosono; Shotaro Tanaka; Takashi Ushiki; Masahiro Hiraoka; Shinae Kizaka-Kondoh
Journal:  PLoS One       Date:  2010-12-23       Impact factor: 3.240

5.  Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment.

Authors:  Shinae Kizaka-Kondoh; Shotaro Tanaka; Masahiro Hiraoka
Journal:  J Toxicol Pathol       Date:  2009-07-07       Impact factor: 1.628

6.  Detection of the onset of ischemia and carcinogenesis by hypoxia-inducible transcription factor-based in vivo bioluminescence imaging.

Authors:  Tetsuya Kadonosono; Takahiro Kuchimaru; Shuichi Yamada; Yumi Takahashi; Atsushi Murakami; Taeko Tani; Hitomi Watanabe; Tomoharu Tanaka; Kiichi Hirota; Masahiro Inoue; Tetsuya Tsukamoto; Takeshi Toyoda; Koji Urano; Kazuhiko Machida; Tomoo Eto; Tomoyuki Ogura; Hideki Tsutsumi; Mamoru Ito; Masahiro Hiraoka; Gen Kondoh; Shinae Kizaka-Kondoh
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

7.  Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model.

Authors:  Ngoc Thi Hong Hoang; Tetsuya Kadonosono; Takahiro Kuchimaru; Shinae Kizaka-Kondoh
Journal:  Cancer Sci       Date:  2016-07-21       Impact factor: 6.716

8.  In vivo imaging of brain ischemia using an oxygen-dependent degradative fusion protein probe.

Authors:  Youshi Fujita; Takahiro Kuchimaru; Tetsuya Kadonosono; Shotaro Tanaka; Yoshiki Hase; Hidekazu Tomimoto; Masahiro Hiraoka; Shinae Kizaka-Kondoh; Masafumi Ihara; Ryosuke Takahashi
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

9.  Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy.

Authors:  H Harada; S Itasaka; Y Zhu; L Zeng; X Xie; A Morinibu; K Shinomiya; M Hiraoka
Journal:  Br J Cancer       Date:  2009-02-17       Impact factor: 7.640

10.  PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.

Authors:  Minoru Inoue; Michio Yoshimura; Minoru Kobayashi; Akiyo Morinibu; Satoshi Itasaka; Masahiro Hiraoka; Hiroshi Harada
Journal:  Sci Rep       Date:  2015-10-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.